Back to catalogue
BiologicalHepatitis, Antiviral & Vaccines
ABDALA®
Cuban recombinant COVID-19 vaccine authorized for emergency use.
Product information
Recombinant COVID-19 vaccine (ABDALA). Developed by CIGB. Authorized for emergency use.
Indications
Prevention of COVID-19 (SARS-CoV-2 infection).
Formulation
Injectable recombinant RBD protein vaccine.
Administration
Intramuscular injection, 3-dose schedule (0, 14, 28 days).
Precautions
Standard vaccine precautions apply. Consult healthcare provider for contraindications.
Product information
- Manufacturer
- CIGB, Havana
- Regulatory status
- Authorized for emergency use in Cuba and several countries
